Dale Han1, Gang Han2, Monica T Duque2, Steven Morrison3, Stanley P Leong4, Mohammed Kashani-Sabet4, John Vetto3, Richard White5, Schlomo Schneebaum6, Barbara Pockaj7, Nicola Mozzillo8, Vernon K Sondak9, Jonathan S Zager9. 1. Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA. handal@ohsu.edu. 2. Department of Epidemiology and Biostatistics, School of Public Health, Texas A&M University, College Station, TX, USA. 3. Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA. 4. California Pacific Medical Center and Research Institute, San Francisco, CA, USA. 5. Levine Cancer Institute, Carolinas Medical Center, Atrium Health, Charlotte, NC, USA. 6. Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. 7. Mayo Clinic, Phoenix, AZ, USA. 8. Instituto Tumori Napoli Fondazione G. Pascale, Naples, Italy. 9. Moffitt Cancer Center, Tampa, FL, USA.
Abstract
BACKGROUND: Sentinel lymph node biopsy (SLNB) is recommended for intermediate thickness melanoma, but for thick melanoma, guidelines are less definitive about the use of SLNB in this population. We present a study on thick melanoma evaluating for prognostic factors. PATIENTS AND METHODS: The Sentinel Lymph Node Working Group database was queried for thick (> 4 mm) melanoma cases that had a SLNB from 1993 to 2018. Clinicopathologic characteristics were correlated with SLN status and melanoma-specific survival (MSS). RESULTS: There were 1235 patients. Median follow-up was 28 months. Median thickness was 5.9 mm, with 956, 175, and 104 cases presenting thickness > 4-8, > 8-12, and > 12 mm, respectively. SLN metastases were seen in 439 of 1235 (35.5%) cases and in 33.9%, 40.6%, and 42.3% of melanomas > 4-8, > 8-12, and > 12 mm, respectively. In each thickness group, MSS was significantly worse for SLN-positive compared with SLN-negative cases (all P < 0.005). Multivariable analysis showed that SLN metastasis, male gender, increasing thickness, lymphovascular invasion, and microsatellitosis significantly predicted worse MSS for melanomas > 4-8 mm, with SLN metastasis showing the greatest risk (HR 2.17, 95% CI 1.64-2.87, P < 0.0001). For melanomas > 8 mm, only SLN metastasis significantly predicted MSS (> 8-12 mm: HR 3.93, 95% CI 2.00-7.73, P < 0.0001; > 12 mm: HR 3.58, 95% CI 1.56-8.22, p < 0.0027). CONCLUSIONS: Thick melanoma patients with SLN metastasis have significantly worse MSS compared with SLN-negative patients, even in the thickest cases, and SLN status is the most powerful and/or only predictor of MSS. Given these results, SLNB shows important prognostic value in this population and is indicated for clinically localized thick melanoma.
BACKGROUND: Sentinel lymph node biopsy (SLNB) is recommended for intermediate thickness melanoma, but for thick melanoma, guidelines are less definitive about the use of SLNB in this population. We present a study on thick melanoma evaluating for prognostic factors. PATIENTS AND METHODS: The Sentinel Lymph Node Working Group database was queried for thick (> 4 mm) melanoma cases that had a SLNB from 1993 to 2018. Clinicopathologic characteristics were correlated with SLN status and melanoma-specific survival (MSS). RESULTS: There were 1235 patients. Median follow-up was 28 months. Median thickness was 5.9 mm, with 956, 175, and 104 cases presenting thickness > 4-8, > 8-12, and > 12 mm, respectively. SLN metastases were seen in 439 of 1235 (35.5%) cases and in 33.9%, 40.6%, and 42.3% of melanomas > 4-8, > 8-12, and > 12 mm, respectively. In each thickness group, MSS was significantly worse for SLN-positive compared with SLN-negative cases (all P < 0.005). Multivariable analysis showed that SLN metastasis, male gender, increasing thickness, lymphovascular invasion, and microsatellitosis significantly predicted worse MSS for melanomas > 4-8 mm, with SLN metastasis showing the greatest risk (HR 2.17, 95% CI 1.64-2.87, P < 0.0001). For melanomas > 8 mm, only SLN metastasis significantly predicted MSS (> 8-12 mm: HR 3.93, 95% CI 2.00-7.73, P < 0.0001; > 12 mm: HR 3.58, 95% CI 1.56-8.22, p < 0.0027). CONCLUSIONS:Thick melanomapatients with SLN metastasis have significantly worse MSS compared with SLN-negative patients, even in the thickest cases, and SLN status is the most powerful and/or only predictor of MSS. Given these results, SLNB shows important prognostic value in this population and is indicated for clinically localized thick melanoma.
Authors: M G Rughani; M C Swan; T S Adams; A Marshall; R Asher; O C Cassell; M R Middleton Journal: Eur J Surg Oncol Date: 2012-05-20 Impact factor: 4.424
Authors: S Ribero; S Osella-Abate; M Sanlorenzo; E Balagna; R Senetta; M T Fierro; G Macripò; L Macrì; A Sapino; P Quaglino Journal: Ann Surg Oncol Date: 2014-11-12 Impact factor: 5.344
Authors: Swapnil D Kachare; Patreek Singla; Nasreen A Vohra; Emmanuel E Zervos; Jan H Wong; Timothy L Fitzgerald Journal: Surgery Date: 2015-06-19 Impact factor: 3.982
Authors: Daniel G Coit; John A Thompson; Mark R Albertini; Christopher Barker; William E Carson; Carlo Contreras; Gregory A Daniels; Dominick DiMaio; Ryan C Fields; Martin D Fleming; Morganna Freeman; Anjela Galan; Brian Gastman; Valerie Guild; Douglas Johnson; Richard W Joseph; Julie R Lange; Sameer Nath; Anthony J Olszanski; Patrick Ott; Aparna Priyanath Gupta; Merrick I Ross; April K Salama; Joseph Skitzki; Jeffrey Sosman; Susan M Swetter; Kenneth K Tanabe; Evan Wuthrick; Nicole R McMillian; Anita M Engh Journal: J Natl Compr Canc Netw Date: 2019-04-01 Impact factor: 11.908
Authors: Maki Yamamoto; Kate J Fisher; Joyce Y Wong; Jonathan M Koscso; Monique A Konstantinovic; Nicholas Govsyeyev; Jane L Messina; Amod A Sarnaik; C Wayne Cruse; Ricardo J Gonzalez; Vernon K Sondak; Jonathan S Zager Journal: Cancer Date: 2015-02-11 Impact factor: 6.860
Authors: Danielle M Bello; Gang Han; Laura Jackson; Kaleigh Bulloch; Stephan Ariyan; Deepak Narayan; Bonnie Gould Rothberg; Dale Han Journal: Ann Surg Oncol Date: 2016-08-15 Impact factor: 5.344
Authors: Eric D Whitman; Vadim P Koshenkov; Brian R Gastman; Deri Lewis; Eddy C Hsueh; Ho Pak; Thomas P Trezona; Robert S Davidson; Michael McPhee; J Michael Guenther; Paul Toomey; Franz O Smith; Peter D Beitsch; James M Lewis; Andrew Ward; Shawn E Young; Parth K Shah; Ann P Quick; Brian J Martin; Olga Zolochevska; Kyle R Covington; Federico A Monzon; Matthew S Goldberg; Robert W Cook; Martin D Fleming; David M Hyams; John T Vetto Journal: JCO Precis Oncol Date: 2021-09-13